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Abstract
Objectives—To explore HIV-infected patients’ attitudes about buprenorphine treatment in
office-based and opioid treatment program (OTP) settings.
Methods—We conducted in-depth qualitative interviews with 29 patients with co-existing HIV
infection and opioid dependence seeking buprenorphine maintenance therapy in office-based and
OTP settings. We used thematic analysis of transcribed audiorecorded interviews to identify
themes.
Results—Patients voiced a strong preference for office-based treatment. Four themes emerged to
explain this preference. First, patients perceived the greater convenience of office-based treatment
as improving their ability to address HIV and other healthcare issues. Second, they perceived a
strong patient-focused orientation in patient-provider relationships underpinning their preference
for office-based care. This was manifest as increased trust, listening, empathy, and respect from
office-based staff and providers. Third, they perceived shared power and responsibility in office-
based settings. Finally, patients viewed office-based treatment as a more supportive environment
for sobriety and relapse prevention. This was partly due to strong therapeutic alliances with office-
based staff and providers who prioritized a harm reduction approach, but also due to the
perception that the office-based settings were “safer” for sobriety, compared with increased
opportunities for purchasing and using illicit opiates in OTP settings.
Conclusions—HIV-infected patients with opioid dependence preferred office-based
buprenorphine because they perceived it as offering a more patient-centered approach to care
compared with OTP referral. Office-based buprenorphine may facilitate engagement in care for
patients with co-existing opioid dependence and HIV infection.
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INTRODUCTION
Opioid dependence is a relapsing-remitting chronic condition (McLellan, Lewis, O'Brien, et
al., 2000; O'Connor, Samet, 2002) afflicting an estimated 213,000 heroin users and 4.7
million nonmedical analgesic users in the United States (SAMHSA, 2009). Though
methadone maintenance treatment with behavioral therapy is effective for treating opioid
dependence (National Consensus Development Panel on Effective Medical Treatment of
Opiate Addiction, 1998; Amato, Davoli, Perucci, et al., 2005) and decreases HIV risk
behaviors and transmission (Camacho, Bartholomew, Joe, et al., 1996; Hartel, Schoenbaum,
1998; Pang, Hao, Mi, et al., 2007), access to treatment remains limited (Friedmann, Lemon,
Stein, et al., 2003; SAMHSA, 2009).
Expanding access to treatment for opioid dependence is particularly important in HIV-
infected populations, where substance use disorder treatment is associated with increased
antiretroviral adherence (Moatti, Carrieri, Spire, et al., 2000; Turner, Laine, Cosler, et al.,
2003; Spire, Lucas, Carrieri, 2007), decreased repeated emergency department visits
(Turner, Laine, Yang, et al., 2003), increased receipt of primary care (Conover, Whetten-
Goldstein, 2002; Messeri, Abramson, Aidala, et al., 2002), decreased hospitalizations
(Palepu, Tyndall, Leon, et al., 2001; Turner, Laine, Yang, et al., 2003) and costs (Palepu,
Tyndall, Leon, et al., 2001). Substance abuse treatment, however, is underutilized among
HIV-infected persons (Burnam, Bing, Morton, et al., 2001; Palepu, Horton, Tibbetts, et al.,
2005; Palepu, Tyndall, Joy, et al., 2006). These and other studies led the Institute of
Medicine to identify substance abuse treatment as a critical component in preventing the
spread of HIV infection (Institute of Medicine, 2001).
The approval of buprenorphine for use by office-based primary care providers offers the
potential for increased access to opioid dependence treatment (Fiellin, 2004). Office-based
buprenorphine treatment has been demonstrated to be feasible and effective in reducing
illicit opioid use (Fiellin, Pantalon, Pakes, et al., 2002; Fudala, Bridge, Herbert, et al., 2003),
safe for use in HIV clinical settings (Sullivan, Barry, Moore, et al., 2006), and associated
with high patient satisfaction rating (Barry, Moore, Pantalon, et al., 2007). It may also
engage more previously untreated opioid-dependent patients compared with methadone
maintenance (Sullivan, Chawarski, O'Connor, et al., 2005).
These studies suggest that at least some patients may prefer integration of treatment for
opioid dependence and other chronic medical conditions. Little is known, however, about a)
why patients might prefer office-based buprenorphine or b) how integrated treatment might
affect treatment for HIV infection. Thus, the objective of this study was to investigate HIV-
infected patients’ attitudes and perceptions about buprenorphine treatment in integrated
settings vs. opioid treatment programs (OTP) and to explore patients’ views of how
integrated care might affect substance abuse treatment and HIV care.
METHODS
Research Setting and Participants
We conducted a qualitative study in the context of a randomized trial of two opioid-
dependence treatment delivery strategies. Two Ryan White-funded HIV primary care clinics
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and one federally certified OTP in Portland, Oregon served as demonstration sites for a
national Health Research and Services Administration (HRSA) Special Projects of National
Significance initiative to promote adoption of buprenorphine in HIV treatment settings.
HIV-infected patients ≥ 18 years old, seeking treatment for a Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) diagnosis of opioid dependence were randomized to
receive office-based buprenorphine from their HIV provider at an HIV clinic or
buprenorphine from an OTP. Patients in the office-based arm of the study received
buprenorphine prescriptions from their HIV providers during clinic visits. Patients receiving
buprenorphine at an OTP were dispensed buprenorphine according to federal methadone
dispensing regulations. All patients received individual substance abuse counseling.
Participants were allowed to cross-over after their initial evaluation. The study protocol was
approved by the Institutional Review Board of Oregon Health & Science University.
Data Sources
In-depth interview guides contained open-ended questions about perceptions and attitudes
toward current and past drug treatment, impact of drug treatment on HIV care, and
organizational factors that influence drug treatment. The interviewer also probed for
potential barriers and facilitators of treatment for opioid dependence in office-based and
OTP settings. An example interview question was, “Please describe your experience getting
drug treatment at this clinic,” with probes: “What services are the most important to you?
Can you tell me about any services that you’ve had problems with?”
One-on-one interviews were conducted by a research assistant with experience in qualitative
interviews, digitally audio-recorded, and transcribed for later analysis. Interviews were
initially conducted 3 and 12 months following study enrollment. Upon preliminary analysis
of the first 19 subjects enrolled, a baseline in-depth interview was added for subsequent
participants. Participants received a $30 gift card for each completed interview. Interview
statements quoted in this manuscript were edited for clarity, as identified by brackets.
Analysis
Audiotaped interviews were transcribed and reviewed for accuracy. We used thematic
analysis to analyze our data and chose an inductive approach, seeking themes that emerged
from the data rather than themes chosen as part of a theoretical model or literature review
(Braun, Clarke, 2006). We analyzed data from a semantic (explicit) perspective using an
essentialist/realist paradigm, as opposed to a constructionist paradigm (i.e., we theorized
motivations, experience and meaning from what participants said rather than theorize the
socio-cultural contexts and structural conditions that enabled the individual narratives). All
interview transcripts were circulated to each member of the team for review. Team members
met to discuss identified themes and resolve doubts or disagreements based on team
discussion in an iterative process. One investigator (WR) then developed an initial coding
scheme based on team discussions and reviewed it with the rest of the team which included
a medical anthropologist (JG). Transcripts were initially coded by one investigator (WR)
using ATLAS.ti software (Muhr, 2004), and then discussed in team meetings with other
investigators to review coding and generate additional themes and sub-themes from
preliminary codes. Doubts or disagreements were resolved by re-reading the original
transcripts until all investigators agreed.
RESULTS
Participants
A total of 32 patients enrolled in the study, 3 of whom withdrew prior to completing a
qualitative interview. We collected at least one in-depth qualitative interview for the
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remaining 29 enrollees, and 79% completed more than 1 interview. Thirteen interviews were
conducted at time of enrollment, 25 at 3 months, and 19 at 12 months. The Table presents
participant characteristics. The majority of participants were male, white race/ethnicity,
injection drug users, and preferred heroin (compared with prescription opiates) as their
opiate of choice. Concomitant stimulant use was common with 55% of participants reporting
recent cocaine or methamphetamine use. Sixty-two percent of participants had prior
treatment experience with methadone maintenance.
Thematic Analysis
Participants voiced an overwhelming preference for office-based care over treatment at an
OTP. Most had previously relapsed following treatment with methadone maintenance and
said they would not have re-attempted treatment at all if only available in an OTP setting.
This view was supported by the fact that 12 of 16 patients randomized to receive
buprenorphine from an OTP crossed-over to office-based buprenorphine (75% of whom had
been previously experienced methadone maintenance), while none of 16 patients
randomized to receive office-based buprenorphine crossed-over to OTP buprenorphine.
“If you put them together [office-based buprenorphine and HIV care], I think it’s
better for everybody, way better for everybody.”
Interviewer (I): “So describe your feelings towards being treated with buprenorphine at this
clinic to treat your opiate dependence.”
Respondent (R): “Blissful, blissful, blissful.”
Reasons for Preferring office-based care
We identified four major themes illuminating why patients preferred office-based treatment
(Figure). They felt that office-based care provided: 1) Greater convenience, which in turn
improved HIV and overall care, 2) Respect, trust, and empathy from providers, which
fostered strong patient-provider relationships, 3) Increased autonomy, which led to shared
power and responsibility, and 4) a harm reduction priority and distance from the drug scene,
which, in combination with these other factors, led to a supportive environment for sobriety.
Theme 1: Greater Convenience Improves Overall Care—Patients repeatedly cited
the greater convenience of office-based care as a primary reason for preferring integrated
care. They believed the increased convenience of receiving all their care in an office-based
setting improved their ability to address both HIV and general healthcare issues. Participants
specifically cited improved access for treatment of acute and chronic conditions and greater
appointment and antiretroviral adherence as benefits of this increased convenience.
“I think [office-based care] is absolutely great. The fact that I don’t have to go to a
methadone situation and be dosed every day, and all that stuff.”
“[Office-based buprenorphine] helps me stay sober so I take my [HIV] medicine.”
“I think the more exposure I have to a clinical setting…the better my care is. I
mean, if I’m here and something is going on, I’ll hang out and go run up and ask
[my provider]…if I’m scared.”
“[Office-based care] makes me show up for my appointments more frequently.”
“Going through my primary care doctor [lets me] kill two birds with one stone,
because I’ve got to get back on my psych meds too.”
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One participant, however, voiced a notable exception to this theme, suggesting that for him
the additional structure and routine of treatment in an OTP setting may have been preferable
for helping him adhere to opiate replacement therapy.
“At first I thought [office-based buprenorphine] would be perfect, because I’ve
been through so many methadone clinics…and I really don’t like coming in every
day. But then when I got the bup…I just didn’t take it. I’m thinking maybe…the
whole idea of a [methadone] clinic and going in there every day… maybe I’m used
to that more than just having to do it myself every day.”
Theme 2: Strong Patient-Provider Relationships—Patients perceived office-based
settings as preferable due to strong interpersonal relationships with HIV clinic staff,
counselors, and providers. Patients gravitated to these therapeutic relationships because of a
greater perception of trust, listening, empathy, and mutual respect with office-based staff,
counselors and providers. Participants repeatedly linked these patient-centered provider
characteristics to their preference for office-based care:
I: “What’s it like getting your buprenorphine treatment here at the clinic with your doctor?”
R: “I think it’s better, because I have a good rapport with my doctor. And…my doctor, you
know, knows all about my history, so it’s not like I can B.S. her or anything.”
“I would rather come here [to the HIV clinic] because…you have that kinship like
with the staff.”
“She [my HIV provider] was real encouraging. I mean, especially because she sat
and she listened, you know, until I was finished.”
In contrast, patients considered the OTP to be less a personal setting for treatment.
“I think it’s better working with your doctor …because there is a kind of a more
personal level. At the [OTP] clinics you just go to the dosing window and the
attitude”
In several cases, patients attributed perceived lack of respect particularly to their co-existing
HIV infection, and voiced concerns about confidentiality in OTP settings.
“I didn’t want anybody to know [I was HIV positive]. If it was up to them they’d
stone me to death. You know, a lot of HIV people were outcasts.”
Theme 3:Shared power and responsibility—Patients perceived greater patient
autonomy and control of their treatment in office-based settings compared with experiences
in OTP settings. They reported this sense of shared responsibility made it easier to stay
sober.
“I think it’s…for a lot of people that are opiate dependent, they have to go every
day and get their medicine. And for the fact that they trust me to do it for a month
and give me the pills in advance, and I don’t have to bring the pills in and have
them counted. And they trust me, so therefore, yeah…it’s nice.”
“He’s [my HIV provider] real open to my concept of things…[so that] in the long run I’m
not getting strung out again.”
Patients greatly disliked what can be seen as a more external locus of control over their
treatment in OTPs.
“One thing, you’re five minutes late they’ll shut the door right in your face.”
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“And if I don't go to certain groups, then they don't give you take-outs and…you
know, it's just a pain in the butt.”
Theme 4: Supportive Environment for Sobriety—Patients perceived the HIV clinic
setting as offering a more welcoming environment to support sobriety. This included both
interpersonal and structural characteristics. Patients described open discussions of substance
use with office-based providers who prioritized harm reduction. They perceived their
providers as having an unconditional commitment to providing care to them.
“…we [my doctor and I] have a real open dialogue about my drug use, which helps
her and helps, you know, gauge where I am, why my body is changing and what all
is going on.”
“I’m more…I’ll open more to him, the [HIV clinic] doctor that takes care of drug
treatment. And, I don’t know, I’m just more comfortable talking about the drugs
and my HIV problems with him.”
This alliance for sobriety extended to relapse prevention. Patients perceived office-based
treatment to prioritize harm reduction (e.g., acknowledgement of reduced overall drug use
over time as improvement in the face of relapse) over complete abstinence as leading to a
more supportive community environment for sobriety and relapse prevention.
“I remember being told at the very beginning, you know, that this was not about
succeed or not succeed. That if I did have problems that they were gonna work with
me. I wasn't gonna get thrown out, or anything.”
“And she's [my HIV provider] made me feel really comfortable knowing that if I…
were to get off it and relapse, or whatever, that she could…you know, that she
could start giving it to me again.”
Open dialogues about relapse were perceived as limited in some OTP settings.
“I got used to being with one case manager there and I relapsed a couple of times.
And…she just dropped me like a dirty rag. You know. And…it kinda left a bad
taste in my mouth.”
While patients also reported strong therapeutic alliances with counselors in OTPs, relapse
prevention at those centers was complicated by environmental factors that increased
opportunities to purchase illicit opiates in those settings.
“…It’s dope central. I mean, you go to any city in the United States and you want
to know where to score big for dope, or something, just go to the methadone
clinic.”
“Watching the people who aren’t really there for recovery…and the buying and
selling of things…It’s just a cycle to watch people who really don’t want to go in
there, and getting it and then selling it and walking right across the street and
buying the illegal part of it …it’s just…ugly.”
DISCUSSION
Patients with co-existing HIV infection and opioid dependence in this study voiced a strong
preference for office-based treatment compared with OTP referral. Though we did not
intentionally construct our interviews to probe for elements of patient-centered care, the
reasons participants gave for their preference echoed four key dimensions of patient-
centeredness described by Mead and Bower: 1) Biopsychosocial perspective—incorporating
medical, mental health, behavioral, and social aspects of a patient’s existence, 2) Viewing
the “patient as a person,” 3) Promoting shared power and responsibility between patients
Korthuis et al. Page 6
J Addict Med. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and health care providers, and 4) Developing a therapeutic alliance between patients and
providers with the common goal of improving health (Mead, Bower, 2000).
Participants in our study perceived the greater convenience of having addiction treatment
and HIV care delivered under one roof as improving the overall quality of their healthcare –
a finding consistent with the biopsychosocial dimension of patient-centered care. Our
patients’ perception of improved care is paralleled by studies showing improved clinical
outcomes with integrated care. For example, patients with substance abuse-related medical
conditions (e.g., Hepatitis C) randomized to receive chemical dependence treatment in a
primary care setting were more likely to achieve abstinence than those treated in an
addiction clinic (Weisner, Mertens, Parthasarathy, et al., 2001). HIV-infected patients may
be even more likely to benefit from integrated treatment (McLellan, Lewis, O'Brien, et al.,
2000).
Interview narratives also yielded strong positive expressions of patients’ relationships with
clinic staff and providers as a major reason for preferring office-based buprenorphine
treatment. The underlying components of these relationships were the trust, respect,
listening, and empathy central to the patient-centered dimension of viewing the “patient as a
person.” This finding echoes a recent patient satisfaction survey among patients receiving
office-based buprenorphine in a primary care clinic which showed high satisfaction scores
for perceptions of physician concern about “you as a patient” and “being treated like a
patient instead of a drug addict” (Barry, Moore, Pantalon, et al., 2007). This dimension of
patient-centeredness has also been associated with improved outcomes. In a national survey
of U.S. adults, patients who reported their provider treated them with dignity had higher
patient satisfaction, medication adherence, and optimal preventive care (Beach, Sugarman,
Johnson, et al., 2005). Among patients attending an urban medical center HIV clinic, those
who reported their provider “knows them as a person” reported greater receipt of
antiretroviral therapy, adherence, and HIV viral suppression (Beach, Keruly, Moore, 2006).
Patients reporting drug or alcohol use in this study, however, were less likely to report that
their provider “knows them as a person.” Little is known about the relationship between
viewing “the patient as a person” in OTP settings or its relationship to substance use
outcomes. The current study raises new research questions about the capacity of providers –
both in office-based and OTP settings – to foster patient-provider relationships where the
patient feels viewed “as a person,” and whether these relationships might be associated with
improved substance use outcomes.
Furthermore, patients in our study perceived themselves as having greater autonomy in the
office-based setting that evoked a sense of shared power and responsibility for health care
with their provider, the third dimension in Mead’s definition of patient-centered care and
one highly associated with patient satisfaction. In a survey of patients receiving primary care
in an urban setting, patient satisfaction was highly associated with their physicians having a
greater participatory decision-making style (Cooper-Patrick, Gallo, Gonzales, et al., 1999).
Likewise, Beach et al. demonstrated that a national sample of U.S. patients who reported
their provider regularly involved them in decisions about their care reported both greater
satisfaction and medication adherence (Beach, Sugarman, Johnson, et al., 2005). Among
patients attending an urban HIV clinic, 63% preferred to share decisions with their doctor,
and they were more likely to adhere to antiretroviral medications and achieve HIV viral
suppression (Beach, Duggan, Moore, 2007). Mutual mistrust between physicians and drug-
using patients, however, impedes attainment of this ideal among drug users hospitalized for
medical issues (Merrill, Rhodes, Deyo, et al., 2002) and likely in other healthcare settings,
as well. The current study suggests that interventions to improve patient autonomy and
participatory decision making around substance use issues may foster improved engagement
in substance use disorder treatment, offering fertile ground for additional research.
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Finally, patients in this study perceived the office-based setting as a supportive community
environment for treatment and recovery due to therapeutic alliances that prioritized harm
reduction and environmental features. The concept of client-provider therapeutic alliance
was originally developed to describe the partnership between client and counselor in moving
toward the goals of psychotherapy. It has since been emphasized in substance use disorder
treatment settings where early therapeutic alliance is associated with improved treatment
retention and substance use outcomes (Diamond, Liddle, Wintersteen, et al., 2006; Ilgen,
Tiet, Finney, et al., 2006; Meier, Donmall, McElduff, et al., 2006). Empiric evidence
evaluating the role of therapeutic alliance in treatment of opioid dependence in primary care
settings is lacking, but patients in this study indicated HIV clinic providers and staff were
strongly aligned with the goal of sobriety and pragmatic in the event of relapse.
Creating a supportive environment for recovery, though, exceeded the bounds of
interpersonal relationship to include a sense of the clinic as a safe place for recovery –
indicating these patients perceived the physical environment and culture of office-based
settings to be as important to their recovery as interpersonal therapeutic alliance with their
providers. Patients in this study particularly valued the relative anonymity of the office-
based settings with regard to other addicts. In contrast, they perceived greater opportunities
to purchase illicit drugs and relapse in the environs surrounding OTPs. This finding raises
further research questions of the role of therapeutic alliance in primary settings, and how
organizational structures, cultures, and environments may influence treatment engagement
and relapse prevention. The Network for the Improvement of Addiction Treatment (NIATx),
for example, uses process improvement strategies to enhance engagement and retention
(Capoccia, Cotter, Gustafson, et al., 2007; McCarty, Gustafson, Wisdom, et al., 2007;
Hoffman, Ford, Choi, et al., 2008). Organizational change strategies appear to be a useful
intervention for improvements in patient-centered care (McCarty, Gustafson, Capoccia, et
al., 2009).
This study’s findings should be interpreted in the context of several limitations. First, the
study population was limited to HIV-infected patients enrolled in a buprenorphine
integration demonstration initiative, most of whom had previously relapsed following
methadone maintenance treatment. We are cautious in interpreting our participant’s
criticisms of OTP. Methadone maintenance is clearly effective in improving both substance
use and behavioral outcomes (National Consensus Development Panel on Effective Medical
Treatment of Opiate Addiction, 1998; Amato, Davoli, Perucci, et al., 2005). Opioid-
dependent patients ranked methadone as preferable to buprenorphine in one study (Luty,
2004), and one of our study participants identified the additional structure of OTP with
increased likelihood of adherence to opiate replacement therapy. Nearly two thirds of
patients in our study, however, had already failed prior attempts at methadone maintenance,
indicating that office-based buprenorphine may offer a means of engaging persons in care
who have not responded to other evidence-based treatment modalities. Patients successfully
treated with office-based buprenorphine may represent a different patient population
compared with those who enroll in methadone maintenance (Sullivan, Chawarski, O'Connor,
et al., 2005). Additional research is required to identify patients more likely to benefit from
office-based vs. OTP treatment approaches.
Second, HIV clinic providers and staff participating in this demonstration project received
substantial training and expert support in implementation of office-based buprenorphine –
both identified as important barriers to widespread implementation of buprenorphine
treatment in primary care (Turner, Laine, Lin, et al., 2005). With regard to both of these
limitations, however, we used a qualitative approach to generate new research questions and
hypotheses for future study rather than achieve a generalizable sample (Crabtree, Miller,
1999). Finally, our findings lack biologic substance use outcome data, which may not
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correlate with patients’ attitudes and perceptions about their treatment. Twelve-month
retention rates, however, were high among our participants (60%), suggesting that larger
studies of patients who have relapsed following methadone maintenance may demonstrate
improved outcomes with more patient-centered approaches to treatment of opioid
dependence.
CONCLUSIONS
Patient-centeredness – focusing health care on the patient’s experience of illness and
promoting systems that meet an individual patient’s needs – is one of the Institute of
Medicine’s key aims for improving the quality of U.S. health care. Patients in this study
preferred office-based buprenorphine treatment because they perceived it be a more patient-
centered alternative to OTP referral. The current study’s findings suggest that additional
work may be required to realize the Institute of Medicine’s call to improve patient-centered
substance abuse treatment (Institute of Medicine, 2006). To the extent that office-based
buprenorphine maintenance remains patient-centered, it may offer an attractive alternative
for engaging patients with co-existing opioid dependence and HIV in treatment. These
findings generate many questions for further research including whether dimensions of
patient-centeredness are associated with HIV and substance use outcomes, how to improve
patient-centered care in both office-based and OTP settings, and whether interventions to
improve the interpersonal and structural aspects of patient-centeredness might lead to
improved outcomes.
Acknowledgments
Supported by the Health Research and Services Administration, Special Projects of National Significance (1-H97-
HA03782-01), and the National Institutes of Health, National Institute on Drug Abuse (K23DA019808 and
R01DA016341). Dr. Gregg’s time was supported by the Oregon Clinical and Translational Research Institute
(OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component
of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Dr. Nicolaidis’ time was
supported by the National Institute of Mental Health (K23MH073008). The authors wish to thank Sarann Bielavitz
for her assistance with manuscript preparation.
REFERENCES
Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic
reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical
practice and research. J Subst Abuse Treat 2005;28(4):321–329. [PubMed: 15925266]
Barry DT, Moore BA, Pantalon MV, et al. Patient satisfaction with primary care office-based
buprenorphine/naloxone treatment. J Gen Intern Med 2007;22(2):242–245. [PubMed: 17356993]
Beach MC, Duggan PS, Moore RD. Is patients' preferred involvement in health decisions related to
outcomes for patients with HIV? J Gen Intern Med 2007;22(8):1119–1124. [PubMed: 17514382]
Beach MC, Keruly J, Moore RD. Is the quality of the patient-provider relationship associated with
better adherence and health outcomes for patients with HIV? J Gen Intern Med 2006;21(6):661–
665. [PubMed: 16808754]
Beach MC, Sugarman J, Johnson RL, Arbelaez JJ, Duggan PS, Cooper LA. Do patients treated with
dignity report higher satisfaction, adherence, and receipt of preventive care? Annals of Family
Medicine 2005;3(4):331–338. [PubMed: 16046566]
Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology
2006;3(2):77–101.
Burnam MA, Bing EG, Morton SC, et al. Use of mental health and substance abuse treatment services
among adults with HIV in the United States. Arch Gen Psychiatry 2001;58(8):729–736. [PubMed:
11483138]
Korthuis et al. Page 9
J Addict Med. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Camacho LM, Bartholomew NG, Joe GW, Cloud MA, Simpson DD. Gender, cocaine and during-
treatment HIV risk reduction among injection opioid users in methadone maintenance. Drug
Alcohol Depend 1996;41(1):1–7. [PubMed: 8793304]
Capoccia VA, Cotter F, Gustafson DH, et al. Making "stone soup": improvements in clinic access and
retention in addiction treatment. Joint Commission Journal on Quality & Patient Safety 2007;33(2):
95–103. [PubMed: 17370920]
Conover CJ, Whetten-Goldstein K. The impact of ancillary services on primary care use and outcomes
for HIV/AIDS patients with public insurance coverage. AIDS Care 2002;14(1)
Cooper-Patrick L, Gallo JJ, Gonzales JJ, et al. Race, gender, and partnership in the patient-physician
relationship. Journal of the American Medical Association 1999;282(6):583–589. [PubMed:
10450723]
Crabtree, B.; Miller, W. Doing Qualitative Research. 2nd ed.. London: Sage; 1999.
Diamond GS, Liddle HA, Wintersteen MB, Dennis ML, Godley SH, Tims F. Early therapeutic alliance
as a predictor of treatment outcome for adolescent cannabis users in outpatient treatment. Am J
Addict 2006;15 Suppl 1:26–33. [PubMed: 17182417]
Fiellin DA. Substance use of disorders in HIV-infected patients: impact and new treatment strategies.
Topics in HIV Medicine 2004;12(3):77–82. [PubMed: 15310938]
Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of
heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2):
231–241. [PubMed: 12014814]
Friedmann PD, Lemon SC, Stein MD, D'Aunno TA. Accessibility of addiction treatment: results from
a national survey of outpatient substance abuse treatment organizations. Health Serv Res
2003;38(3):887–903. [PubMed: 12822917]
Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-
tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349(10):949–958. [see
comment]. [PubMed: 12954743]
Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of
experience in the Bronx, New York City. Public Health Rep 1998;1:107–115. [PubMed: 9722816]
Hoffman KA, Ford JH 2nd, Choi D, Gustafson DH, McCarty D. Replication and sustainability of
improved access and retention within the Network for the Improvement of Addiction Treatment.
Drug Alcohol Depend 2008;98(1–2):63–69. [comment]. [PubMed: 18565693]
Ilgen M, Tiet Q, Finney J, Moos RH. Self-efficacy, therapeutic alliance, and alcohol-use disorder
treatment outcomes. J Stud Alcohol 2006;67(3):465–472. [PubMed: 16608158]
No time to lose: Getting more from HIV prevention. Washington, D.C: National Academy Press;
2001. Institute of Medicine.
Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm
Series. Washington, D.C: The National Academies Press; 2006. Institute of Medicine.
Luty J. Treatment preferences of opiate-dependent patients. Psychiatric Bulletin 2004;28(2):47–50.
McCarty D, Gustafson D, Capoccia VA, Cotter F. Improving care for the treatment of alcohol and
drug disorders. J Behav Health Serv Res 2009;36(1):52–60. [PubMed: 18259871]
McCarty D, Gustafson DH, Wisdom JP, et al. The Network for the Improvement of Addiction
Treatment (NIATx): enhancing access and retention. Drug Alcohol Depend 2007;88(2–3):138–
145. [PubMed: 17129680]
McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness:
implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical
Association 2000;284(13):1689–1695. [see comment]. [PubMed: 11015800]
Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature.
Soc Sci Med 2000;51(7):1087–1110. [PubMed: 11005395]
Meier PS, Donmall MC, McElduff P, Barrowclough C, Heller RF. The role of the early therapeutic
alliance in predicting drug treatment dropout. Drug Alcohol Depend 2006;83(1):57–64. [PubMed:
16298088]
Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of
drug users: the keys to the "narc" cabinet. J Gen Intern Med 2002;17(5):327–333. [PubMed:
12047728]
Korthuis et al. Page 10
J Addict Med. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Messeri PA, Abramson DM, Aidala AA, Lee F, Lee G. The impact of ancillary HIV services on
engagement in medical care in New York City. AIDS Care 2002;14(1)
Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. The Manif 2000 study group.
Adherence to HAART in French HIV-infected injecting drug users: the contribution of
buprenorphine drug maintenance treatment. AIDS 2000;14(2):151–155. [PubMed: 10708285]
Muhr, T. User's Manual for ATLAS.ti 5.0. Berlin: ATLAS.ti Scientific Software Development GmbH;
2004.
National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.
Effective medical treatment of opiate addiction. JAMA 1998;280(22):1936–1943. [PubMed:
9851480]
O'Connor PG, Samet JH. Substance abuse: the expanding role of general internal medicine. J Gen
Intern Med 2002;17(5):398–399. [PubMed: 12047739]
Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Substance abuse treatment and hospitalization
among a cohort of HIV-infected individuals with alcohol problems. Alcoholism: Clinical &
Experimental Research 2005;29(3):389–394.
Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among
HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug
Alcohol Depend 2006;84(2):188–194. [PubMed: 16542797]
Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users.
Can Med Assoc J 2001;165(4):415–420. [PubMed: 11531049]
Pang L, Hao Y, Mi G, et al. Effectiveness of first eight methadone maintenance treatment clinics in
China. AIDS 2007;21 Suppl 8:S103–S107. [PubMed: 18172377]
SAMHSA. Results from the 2008 National Survey on Drug Use and Health: National Findings.
Rockville, MD: Office of Applied Studies; 2009.
Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid
substitution treatment (OST). International Journal of Drug Policy 2007;18(4):262–270. [PubMed:
17689374]
Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical
care. Clin Infect Dis 2006;43 Suppl 4:S184–S190. [PubMed: 17109305]
Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based
buprenorphine treatment of opioid dependence: is it associated with new patients entering into
treatment? Drug Alcohol Depend 2005;79(1):113–116. [PubMed: 15943950]
Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care
delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med 2003;18(4):
248–257. [PubMed: 12709091]
Turner BJ, Laine C, Lin Y-T, Lynch K. Barriers and facilitators to primary care or human
immunodeficiency virus clinics providing methadone or buprenorphine for the management of
opioid dependence. Arch Intern Med 2005;165(15):1769–1776. [PubMed: 16087826]
Turner BJ, Laine C, Yang CP, Hauck WW. Effects of long-term, medically supervised, drug-free
treatment and methadone maintenance treatment on drug users' emergency department use and
hospitalization. Clin Infect Dis 2003;37(5):15.
Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with
addiction treatment: a randomized controlled trial. Journal of the American Medical Association
2001;286(14):1715–1723. [PubMed: 11594896]
Korthuis et al. Page 11
J Addict Med. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
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Table
Participant Characteristics (n=29).
N (%)
Median age in years (range) 41 (20–58)
Male gender 23 (79)
Race/Ethnicity
     White 18 (63)
     African-American 3 (10)
     Native American 3 (10)
     Asian 3 (10)
     Latino 2 (7)
Opiate of choice
     Heroin 20 (69)
     Prescription opiate analgesics 5 (31)
Concurrent Drug Use
     Cocaine 12 (41)
     Methamphetamine 4 (14)
     Sedatives 8 (28)
Current IDU 23 (79)
Past Methadone Maintenance 18 (62)
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